Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Roche's Cobas TaqMan HIV-1 Test 2.0

Premium

Roche this week announced the US availability of the Cobas TaqMan HIV-1 Test v2.0 for use with the High Pure System.

Approved by the US Food and Drug Administration in July, the test is based on the company's proprietary dual-target approach, and enables labs to combine the FDA-approved High Pure process for manual viral nucleic acid preparation with the Cobas TaqMan 48 automated real-time PCR analyzer for amplification and detection.

The assay targets two highly conserved regions of the HIV-1 genome and avoids any regions that are current drug targets, thus providing reliable test results even when mutations are present, Roche said.

The new test completes Roche's High Pure System, which also provides FDA-approved processes for manual specimen preparation for hepatitis C and hepatitis B testing via automated real-time PCR. Labs can now consolidate HIV-1 amplification and detection on the Cobas TaqMan 48 along with HCV and HBV viral load monitoring assays.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.